EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation therapy targets tough lung cancers in early trial
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3, found in small cell lung cancer and similar tumors. About 138 adults with advanced cancer that has not responded to standard treatments will receive the drug to check safety, …
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New hope for rare cancer: Triple-Drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in 34 people with a rare, advanced cancer called extrapulmonary neuroendocrine carcinoma that has not responded to standard first-line therapy. The main goal is to see if the combination can sh…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug targets hard-to-treat neuroendocrine cancers in early trial
Disease control Recruiting nowThis study tests a new drug, peluntamig, in people with advanced neuroendocrine cancers (like small cell lung cancer) that have a specific marker called DLL3. The trial has two parts: first finding the safest dose, then testing it alone or with chemotherapy. About 203 participant…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated May 01, 2026 16:00 UTC